Des-enkephalin-gamma-endorphin in the Treatment of Schizophrenia

Ninety-three patients with an exacerbation of chronic schizophrenia were included in a 4 week trial comparing placebo with 1, 3 and 10 mg des enkephalin-γ-endorphin (DEγE; β-lipotrophin 66–77; Org 5878) per day (i.m.). Maintenance antipsychotic and other medications were continued unchanged. Treatment effects were assessed by means of the Comprehensive Psychopathological Rating Scale—subscale schizophrenia (CPRS-S), Brief Psychiatric Rating Scale (BPRS) and Global Assessment Scale (GAS) rating scales at weekly intervals. Safety data, i.e. laboratory investigations, vital signs and ECG recordings, were assessed before and during the trial. Side-effects were evaluated by means of a Record of Symptoms Emerging.Sixty-eight patients completed the trial, the reason for drop-out mainly being inadequate treatment effects and refusal of medication administration. One patient violated the protocol. After 4 weeks of treatment the mean CPRSS score of the group receiving 10 mg DEγE daily had decreased statistically significantly more than the corresponding score of the placebo group (p < 0·01). The same trend was apparent with BPRS (p = 0·08) and GAS (p > 0·1) scores. Therefore, the study should be considered inconclusive. No clinically relevant side-effects attributable to DEγE were observed.